CytoDyn CYDY
OTC CYDY
$0.25 0.00 (-1.77%)
As of: Oct 21, 2026 · 12:21 PM EDT

CytoDyn (CYDY) EBIT Margin (2021 - 2022)

Updated

CytoDyn (CYDY) reported EBIT Margin of -232494.12% for fiscal Q4 2022 (quarter ended May 31, 2022).

Analysis

CytoDyn (CYDY) EBIT Margin (2021 - 2022) Analysis & Trends

For FY2022 (ended May 31, 2022), CytoDyn posted EBIT Margin of -48468.00%.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT Margin (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn 51.16%
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn 28.21%
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn 37.86%
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn -3.52%
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn 32.97%
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn 20.57%
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn 34.95%
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn -133.21%
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn 28.37%
10 CytoDyn 340.03 Mn 291.18 Mn - -
Historic Data

Historic Data

Download Data
DateValue
May 31, 2022 -232,494.12%
Nov 30, 2021 -11,254.22%
Aug 31, 2021 -52,773.17%
API Access

CytoDyn EBIT Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebit-margin&ticker=CYDY&period=max&api_key=YOUR_API_KEY